日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Correction: Wu et al. WIP1 Inhibition by GSK2830371 Potentiates HDM201 Through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells. Cancers 2021, 13, 3876

更正:Wu 等人,《GSK2830371 对 WIP1 的抑制作用通过增强肝腺癌细胞中 p53 的磷酸化和激活来增强 HDM201 的作用》,Cancers 2021, 13, 3876

Wu, Chiao-En; Mahdi, Ahmed Khairallah; Huang, Chen-Yang; Chen, Chiao-Ping; Pan, Yi-Ru; Chang, John Wen-Cheng; Chen, Jen-Shi; Yeh, Chun-Nan; Lunec, John

Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

更正:靶向 WEE1 激酶作为高危和复发性急性淋巴细胞白血病中一种不依赖于 p53 的治疗策略

Bell, Hayden L; Blair, Helen J; Singh, Mankaran; Moorman, Anthony V; Heidenreich, Olaf; van Delft, Frederik W; Lunec, John; Irving, Julie A E

Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia

利用 Siremadlin 靶向 MDM2-p53 相互作用:一种治疗 TP53 野生型慢性淋巴细胞白血病的有前景的治疗策略

Erhan Aptullahoglu, Mohammed Howladar, Jonathan P Wallis, Helen Marr, Scott Marshall, Julie Irving, Elaine Willmore, John Lunec

Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

联合使用 p53 激活和 BCL-xL/BCL-2 抑制作为高风险和复发性急性淋巴细胞白血病的治疗策略

Hayden L Bell, Helen J Blair, Samantha J Jepson Gosling, Martin Galler, Daniel Astley, Anthony V Moorman, Olaf Heidenreich, Gareth J Veal, Frederik W van Delft, John Lunec, Julie A E Irving

A Systematic Review of the Molecular Mechanisms Involved in the Association Between PCOS and Endometrial and Ovarian Cancers

多囊卵巢综合征与子宫内膜癌和卵巢癌关联中涉及的分子机制的系统性综述

Zanjirband, M; Nasr-Esfahani, M H; Curtin, N J; Drew, Y; Sharma Saha, S; Adibi, P; Lunec, J

RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia

RNA 测序揭示 TP53 野生型慢性淋巴细胞白血病中对 MDM2 拮抗剂 Idasanutlin 产生耐药性的候选基因和通路

Erhan Aptullahoglu, Sirintra Nakjang, Jonathan P Wallis, Helen Marr, Scott Marshall, Elaine Willmore, John Lunec

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

更正:在卵巢癌治疗中,rucaparib(Rubraca)与MDM2抑制剂Nutlin-3和RG7388联合治疗具有协同作用和降低剂量的潜力。

Zanjirband, Maryam; Curtin, Nicola; Edmondson, Richard J; Lunec, John

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage

出版商更正:DHODH抑制剂通过阻断p53降解来增加p53合成并增强肿瘤细胞杀伤作用。

Ladds, Marcus J G W; van Leeuwen, Ingeborg M M; Drummond, Catherine J; Chu, Su; Healy, Alan R; Popova, Gergana; Fernández, Andrés Pastor; Mollick, Tanzina; Darekar, Suhas; Sedimbi, Saikiran K; Nekulova, Marta; Sachweh, Marijke C C; Campbell, Johanna; Higgins, Maureen; Tuck, Chloe; Popa, Mihaela; Safont, Mireia Mayoral; Gelebart, Pascal; Fandalyuk, Zinayida; Thompson, Alastair M; Svensson, Richard; Gustavsson, Anna-Lena; Johansson, Lars; Färnegårdh, Katarina; Yngve, Ulrika; Saleh, Aljona; Haraldsson, Martin; D'Hollander, Agathe C A; Franco, Marcela; Zhao, Yan; Håkansson, Maria; Walse, Björn; Larsson, Karin; Peat, Emma M; Pelechano, Vicent; Lunec, John; Vojtesek, Borivoj; Carmena, Mar; Earnshaw, William C; McCarthy, Anna R; Westwood, Nicholas J; Arsenian-Henriksson, Marie; Lane, David P; Bhatia, Ravi; McCormack, Emmet; Laín, Sonia

Impact of retrotransposon protein L1 ORF1p expression on oncogenic pathways in hepatocellular carcinoma: the role of cytoplasmic PIN1 upregulation

逆转座子蛋白 L1 ORF1p 表达对肝细胞癌致癌途径的影响:细胞质 PIN1 上调的作用

Bassier Zadran #, Praveen Dhondurao Sudhindar #, Daniel Wainwright, Yvonne Bury, Saimir Luli, Rachel Howarth, Misti Vanette McCain, Robyn Watson, Hannah Huet, Fanni Palinkas, Rolando Berlinguer-Palmini, John Casement, Derek A Mann, Fiona Oakley, John Lunec, Helen Reeves, Geoffrey J Faulkner, Ruchi S

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

以 WEE1 激酶为靶点,作为高危复发性急性淋巴细胞白血病的 p53 独立治疗策略

Hayden L Bell, Helen J Blair, Mankaran Singh, Anthony V Moorman, Olaf Heidenreich, Frederik W van Delft, John Lunec, Julie A E Irving